(Crenezumab)Biosimilar Reference Antibody-GS40152 新品

货号：GS40152

Crenezumab is an investigational humanized monoclonal antibody that was developed for the treatment of Alzheimer's disease (AD). It represents an early-to-mid-stage therapeutic candidate within the class of anti-amyloid beta (Aβ) antibodies, designed to target and promote the clearance of soluble Aβ oligomers and protofibrils—forms believed to be particularly toxic to neurons and to drive disease progression. Despite demonstrating a favorable safety profile in initial studies, its development program was ultimately discontinued after two large Phase III clinical trials (CREAD 1 and CREAD 2) failed to meet their primary endpoints of slowing cognitive and functional decline in patients with early (prodromal to mild) Alzheimer's disease.